Demographic determinants of survival in osteosarcoma

Annals of the Academy of Medicine Singapore

Volumn 41, Issue 9, 2012, Pages 390-399

  Nathan, Saminathan S ^a   Healey, John H ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cancer; Ethnicity; Race; Sarcoma; Socioeconomic

Indexed keywords

ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHILD; DEMOGRAPHY; ETHNICITY; FEMALE; GENDER; HISTOLOGY; HUMAN; HUMAN TISSUE; INCOME; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; OSTEOSARCOMA; PRESCHOOL CHILD; RACE DIFFERENCE; SCHOOL CHILD; SOCIAL STATUS;

EID: 84867153417     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Jaffe N. Recent advances in the chemotherapy of metastatic osteogenic sarcoma. Cancer 1972;30:1627-31.
2. Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Patho Lab Med 1977;101:14-8.
3. Marcove RC, Mike V, Hajek JV, Levin AG, Hutter RV. Osteogenic sarcoma under the age of twenty-one. A review of one hundred and forty-fi ve operative cases. J Bone Joint Surg Am 1970;52:411-23.
4. Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992;10:5-15.
5. Rosen G, Nirenberg A, Caparros B, Juergens H, Kosloff C, Mehta BM, et al. Osteogenic sarcoma: eight-percent, three-year, disease-free survival with combination chemotherapy (T-7). Natl Cancer Ins Monogr 1981;56:213-20.
6. Zalupski MM, Rankin C, Ryan JR, Lucas DR, Muler J, Lanier KS, et al. Adjuvant therapy of osteosarcoma--A Phase II trial: Southwest Oncology Group study 9139. Cancer 2004;100:818-25.
7. Bacci G, Ferrari S, Longhi A, Picci P, Mercuri M, Alvegard TA, et al. High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. J Chemother 2002;14:198-206.
8. Bacci G, Briccoli A, Ferrari S, Longhi A, Mercuri M, Capanna R, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. Eur J Cancer 2001;37:2030-9.
9. United States Cancer Statistics: 2000 Incidence: National Cancer InstituteNorth American Association of Central Cancer Registries, 2000.
10. The Surveillance, Epidemiology, and End Results (SEER) Program. National Cancer Institute, 2004.
11. Huvos AG. Bone tumors-diagnosis, treatment & prognosis. 2nd ed. WB Saunders Company, 1991.
12. Jaffe HL. Tumors and tumorous conditions of the bones and joints. Lea and Febiger, 1958.
13. Bureau of Economic Analysis: U.S. Department of Commerce, 2004.
14. Greene FL. AJCC cancer staging manual. 6th ed. New York: Springer-Verlag Inc, 2002.
15. Huvos AG, Butler A, Bretsky SS. Osteogenic sarcoma in the American black. Cancer 1983;52:1959-65.
16. Guo W, Xu W, Huvos AG, Healey JH, Feng C. Comparative frequency of bone sarcomas among different racial groups. Chin Med J (Engl) 1999;112:1101-4.
17. Simon MA, Aschliman MA, Thomas N, Mankin HJ. Limb-salvage treatment versus amputation for osteosarcoma of the distal end of the femur. J Bone Joint Surg Am 1986;68:1331-7.
18. Gherlinzoni F, Picci P, Bacci G, Campanacci D. Limb sparing versus amputation in osteosarcoma. Correlation between local control, surgical margins and tumor necrosis: Istituto Rizzoli experience. Ann Oncol 1992;3Suppl 2:S23-7.
19. Enneking WF. Musculoskeletal tumor surgery. 1st ed. Churchill Livingstone, 1983.
20. Teng YS. Human liver aldehyde dehydrogenase in Chinese and Asiatic Indians: gene deletion and its possible implications in alcohol metabolism. Biochem Genet 1981;19:107-14.
21. Lai HC, Lai MP, Leung KS. Glucose-6-phosphate dehydrogenase defi ciency in Chinese. J Clin Pathol 1968;21:44-7.
22. Parekh HK, Sladek NE. NADPH-dependent enzyme-catalyzed reduction of aldophosphamide, the pivotal metabolite of cyclophosphamide. Biochem Pharmacol 1993;46:1043-52.
23. Ganey PE, Thurman RG. Ethanol potentiates doxorubicin-induced inhibition of cell survival in cultured Chinese hamster ovary cells. Cancer Res 1991;51:2036-40.
24. Liu Y, Thurman RG. Potentiation of adriamycin toxicity by ethanol in perfused rat liver. J Pharmacol Exp Ther 1992;263:651-6.